TQ Quiz | Advances in Therapeutics in Ocular Disease (Orlando 2023) by Events@optometricedu.com | Jun 15, 2023 | 2023 Orlando, TQ Courses | 0 comments "*" indicates required fields HiddenAdvances in Therapeutics in Ocular DiseaseHiddenDate (Hidden) MM slash DD slash YYYY HiddenEvent Date (Hidden) MM slash DD slash YYYY HiddenEvent 60 days past date (Hidden) MM slash DD slash YYYY HiddenEvent Date Difference (Hidden)1. Humira (adalimumab) subcutaneous injection is on label for which ocular diagnosis?* A - Noninfectious posterior uveitis B - Diabetic macular edema C - RPE65 biallelic mutation D - Neovascular macular degeneration 2. What is the difference between generic latanoprost 0.005% and Xelpros (latanoprost ophthalmic emulsion 0.005%)?* A - Mechanism of action B - Preservative C - Active ingredient D - Dosage 3. The most common side effect of rho kinase inhibitors is:* A - Anterior uveitis B - Conjunctival hyperemia C - Intraocular inflammation D - Iris color change 4. What is the trade name of the intracameral bimatoprost sustained-release implant?* A - Durysta B - Durezol C - Dexycu D - DARPin 5. Contraindications to use of Eylea (aflibercept) include:* A - Previous ocular surgery B - Active intraocular inflammation C - Cataract D - Hyperopia 6. Which of the following is NOT part of the general trend in the development of new therapies in retinal vascular disease?* A - Decreased amount of time between treatments B - Development of alternative routes of administration of medication C - Improvement of patient quality of life D - Reduction in the cost of treatment 7. Advantages of smaller molecule anti-VEGF agents include:* A - Higher systemic exposure B - Slower clearance C - Improved tissue penetration D - Greater required medication volume 8. Which of the following medications is a preservative-free prostaglandin analog?* A - Travatan Z (travoprost ophthalmic solution) 0.004% B - Iyuzeh (latanoprost ophthalmic solution) 0.005% C - Lumigan (bimatoprost ophthalmic solution) 0.01% D - Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% 9. Rocklatan (netarsudil 0.02%/latanoprost 0.005%) dosage is correctly described as:* A - Every other day B - Once daily in the evening C - Twice daily D - Three times daily 10. Emerging treatment options for presbyopia include which of the following classes of medications?* A - Beta blockers B - Cholinergics C - Steroids D - Fluoroquinolones 11. Oxervate (cenegermin-bkbj ophthalmic solution 0.002%) is on label for the treatment of:* A - Thyroid eye disease B - Neurotrophic keratitis C - Dry eye disease D - Herpes simplex epithelial keratitis 12. What is the name of the FDA-approved dual-pathway inhibiting agent for the treatment of neovascular macular degeneration and diabetic macular edema?* A - Faricimab B - Tocilizumab C - Teprotumumab D - Bevacizumab 13. Adverse effects of intravitreal anti-VEGF injection include all but which of the following?* A - Elevated intraocular pressure B - Endophthalmitis C - Subconjunctival hemorrhage D - Myopia 14. Syfovre (pegcetacoplan) is FDA approved for the treatment of:* A - Neovascular AMD B - Geographic atrophy C - Intermediate stage non-exudative AMD D - Cystoid macular edema 15. Tepezza (teprotumumab-trbw) is administered by which route?* A - Topical ophthalmic route B - Oral route C - Intravenous infusion D - Subcutaneous injection 16. Side effects of systemically administered steroids include all of the following, EXCEPT:* A - Weight loss B - Hyperglycemia C - Lower resistance to infection D - Changes in mood 17. Long-term use of topical ocular medications preserved with benzalkonium chloride (BAK) may cause which of the following?* A - Decreased goblet cell density B - Increased intraocular pressure C - Cystoid macular edema D - Hyperopic shift 18. Which class of intraocular pressure lowering medication is associated with the best adherence at FDA approved dosing?* A - Carbonic anhydrase inhibitors B - Alpha adrenergic agonists C - Prostaglandin analogs D - Fixed combination medications 19. Activation of the complement system ultimately leads to which cellular process?* A - Apoptosis B - Mitosis C - Respiration D - Transcription 20. FDA-approved biosimilars are available for which of the following anti-VEGF agents?* A - Ranibizumab B - Aflibercept C - Brolucizumab D - Faricimab Personal InformationName* First Last Email* Phone*OE Tracker # License # Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationHiddenRetake Code Advances in Therapeutics in Ocular Disease | TQ Credit*After 8/16/2023, pricing will increase to $30. Price: (Past 60 Days) Advances in Therapeutics in Ocular Disease | TQ CreditThis course was presented over 60 days ago. Due to this late submission of TQ, your TQ credit price is $30. Price: Retake Discount Price: (Past 60 Days) Retake Discount Price: Paying Via Credit Card A Paypal account is not required to pay using the button below. To pay using a credit card, click the Paypal button below. A new window will appear and a button "Pay with Debit or Credit Card" is available at the bottom of that window for your convenience. Payment MethodPayPal CheckoutCredit Card American ExpressDiscoverMasterCardVisaSupported Credit Cards: American Express, Discover, MasterCard, Visa Card Number Card Number Expiration Date Expiration Date Security Code Security Code Cardholder Name HiddenCourse Information (HIDDEN)HiddenCourse Name (HIDDEN) HiddenRetake Code (HIDDEN) HiddenQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/) HiddenCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
